Choroidal Thickness and Visual Prognosis in Type 1 Lesion Due to Neovascular Age-Related Macular Degeneration

Abstract

Purpose

To evaluate the association between subfoveal choroidal thickness and the visual outcome in eyes with type 1 choroidal neovascularization (CNV) due to neovascular age-related macular degeneration (nAMD).

Methods

This was a retrospective, longitudinal, cross-sectional study including patients diagnosed with nAMD type 1 lesions managed with intravitreal injections of ranibizumab in a PRN strategy during 24 months. Retrospective chart review of patients with type 1 CNV recording the visual acuity, number of intravitreal injections, multimodal imaging data, and follow-up period was performed. Subfoveal choroidal thickness was measured using enhanced depth imaging scans obtained with spectral-domain optical coherence tomography.

Results

Twenty-five eyes of 21 patients were included. The mean baseline logMAR best-corrected visual acuity was 0.52 (+0.35) (median 0.5; range 0.1-1; interquartile range (IQR) 0.3-0.8) and improved to 0.39 (+0.39) (median 0.4; range 0.1-1; IQR 0.2-0.5) by the end of the follow-up (p = 0.038). Subfoveal choroidal thickness was 202.8 (+60.3) μm (median 218; range 81-285; IQR 146-258). Statistical mixed effects model demonstrated an association between rate of improvement of visual acuity with subfoveal choroidal thickness after 24 months (p<0.001) (95% confidence interval 0.0002-0.0001 logMAR month μm); higher thickness values were correlated with better visual acuity.

Conclusions

Thicker subfoveal choroid was associated with better visual outcomes in patients with type 1 CNV due to nAMD following a strict PRN regimen with intravitreal ranibizumab at 24 months of follow-up.

Keywords

Get full access to this article

View all access options for this article.

References

Bressler

Age-related macular degeneration is the leading cause of blindness….

JAMA 2004;291(15):1900–1901

Nowak

Age-related macular degeneration (AMD): pathogenesis and therapy.

Pharmacol Rep 2006;58(3):353–363

McLeod

Grebe

Bhutto

Merges

Baba

Lutty

Relationship between RPE and choriocapillaris in age-related macular degeneration.

Invest Ophthalmol Vis Sci 2009;50(10):4982–4991

Coleman

Silverman

Rondeau

Lloyd

Khanifar

Chan

Age-related macular degeneration: choroidal ischaemia?

Br J Ophthalmol 2013;97(8):1020–1023

Grunwald

Metelitsina

et al.

Association of risk factors for choroidal neovascularization in age-related macular degeneration with decreased foveolar choroidal circulation.

Am J Ophthalmol 2010;150(1):40–47e2

Grunwald

Hariprasad

DuPont

et al.

Foveolar choroidal blood flow in age-related macular degeneration.

Invest Ophthalmol Vis Sci 1998;39(2):385–390

Mori

Gehlbach

Ito

Yoneya

Decreased arterial dye-filling and venous dilation in the macular choroid associated with age-related macular degeneration.

Retina 2005;25(4):430–437

Spaide

Koizumi

Pozzoni

Enhanced depth imaging spectral-domain optical coherence tomography (erratum 2009;148(2):325).

Am J Ophthalmol 2008;146(4):496–500

Margolis

Spaide

A pilot study of enhanced depth imaging optical coherence tomography of the choroid in normal eyes.

Am J Ophthalmol 2009;147(5):811–815

10.

Chung

Kang

Lee

Kim

Choroidal thickness in polypoidal choroidal vasculopathy and exudative age-related macular degeneration.

Ophthalmology 2011;118(5):840–845

11.

Wood

Binns

Margrain

et al.

Retinal and choroidal thickness in early age-related macular degeneration.

Am J Ophthalmol 2011;152(6):1030–1038e2

12.

Shin

Kwon

Byeon

Association between choroidal thickness and the response to intravitreal ranibizumab injection in age-related macular degeneration.

Acta Ophthalmol 2015;93(6):524–532

13.

Kang

Kwon

Lee

Subfoveal choroidal thickness as a potential predictor of visual outcome and treatment response after intravitreal ranibizumab injections for typical exudative age-related macular degeneration.

Am J Ophthalmol 2014;157(5):1013–1021

14.

Razavi

Souied

Darvizeh

Querques

Assessment of Choroidal Topographic Changes by Swept-Source Optical Coherence Tomography After Intravitreal Ranibizumab for Exudative Age-Related Macular Degeneration.

Am J Ophthalmol 2015;160(5):1006–1013

15.

Rosenfeld

Brown

Heier

et al;

MARINA Study Group.

Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355(14):1419–1431

16.

Brown

Kaiser

Michels

et al;

ANCHOR Study Group.

Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355(14):1432–1444

17.

Regillo

Brown

Abraham

et al.

Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1.

Am J Ophthalmol 2008;145(2):239–248

18.

Schmidt-Erfurth

Eldem

Guymer

et al.

Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study.

Ophthalmology 2011;118(5):831–839

19.

Fung

Lalwani

Rosenfeld

et al.

An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration.

Am J Ophthalmol 2007;143(4):566–583

20.

Holz

Amoaku

Donate

et al;

SUSTAIN Study Group.

Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study. Ophthalmology 2011;118(4):663–671

21.

Lalwani

Rosenfeld

Fung

et al.

A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study.

Am J Ophthalmol 2009;148(1):43–58e1

22.

Engelbert

Zweifel

Freund

Long-term follow-up for type 1 (subretinal pigment epithelium) neovascularization using a modified “treat and extend” dosing regimen of intravitreal antivascular endothelial growth factor therapy.

Retina 2010;30(9):1368–1375

23.

Rofagha

Bhisitkul

Boyer

Sadda

Zhang

SEVEN-UP Study Group.

Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology 2013;120(11):2292–2299

24.

Freund

Zweifel

Engelbert

Do we need a new classification for choroidal neovascularization in age-related macular degeneration? Retina.

2010;30(9):1333–1349

25.

Cnaan

Laird

Slasor

Using the general linear mixed model to analyse unbalanced repeated measures and longitudinal data.

Stat Med 1997;16(20):2349–2380

26.

Coleman

Chan

Ferris

III Chew

Age-related macular degeneration.

Lancet 2008;372(9652):1835–1845

27.

Nowak

Oxidative stress, polyunsaturated fatty acids-derived oxidation products and bisretinoids as potential inducers of CNS diseases: focus on age-related macular degeneration.

Pharmacol Rep 2013;65(2):288–304

28.

Nowak

Age-related macular degeneration (AMD): pathogenesis and therapy.

Pharmacol Rep 2006;58(3):353–363

29.

Ehrlich

Kheradiya

Winston

Moore

Wirostko

Harris

Age-related ocular vascular changes.

Graefes Arch Clin Exp Ophthalmol 2009;247(5):583–591

30.

Grunwald

Hariprasad

DuPont

Effect of aging on foveolar choroidal circulation.

Arch Ophthalmol 1998;116(2):150–154

31.

Linsenmeier

Padnick-Silver

Metabolic dependence of photoreceptors on the choroid in the normal and detached retina.

Invest Ophthalmol Vis Sci 2000;41(10):3117–3123

32.

Koizumi

Kano

Yamamoto

Saito

Maruko

Sekiryu

Okada

Iisa

Subfoveal Choroidal Thickness during Aflibercept Therapy for Neovascular Age-Related Macular Degeneration.

Ophthalmology 2016;123(3):617–624

33.

Papadopoulou

Mendrinos

Mangioris

Donati

Pournaras

Intravitreal ranibizumab may induce retinal arteriolar vasoconstriction in patients with neovascular age-related macular degeneration.

Ophthalmology 2009;116(9):1755–1761

34.

Mazaraki

Fassnacht-Riederle

Blum

Becker

Michels

Change in choroidal thickness after intravitreal aflibercept in pretreated and treatment-naive eyes for neovascular age-related macular degeneration.

Br J Ophthalmol 2015;99(10):1341–1344

35.

Rayess

Houston

III Gupta

Regillo

Treatment outcomes after 3 years in neovascular age-related macular degeneration using a treat-and-extend regimen.

Am J Ophthalmol 2015;159(1):3–8e1

36.

Gass

Biomicroscopic and histopathologic considerations regarding the feasibility of surgical excision of subfoveal neovascular membranes.

Am J Ophthalmol 1994;118(3):285–298

37.

Grossniklaus

Gass

JDM

Clinicopathologic correlations of surgically excised type 1 and type 2 submacular choroidal neovascular membranes.

Am J Ophthalmol 1998;126(1):59–69